AI assistant
HAEMONETICS CORP — Director's Dealing 2023
Sep 7, 2023
31565_dirs_2023-09-07_37332a51-dd8c-472c-8db4-9c5137be32e8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2023-09-05
Reporting Person: Dockendorff Charles J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-09-05 | Common Stock | S | 10215 | $87.68 | Disposed | 2226 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 17915 | Indirect |
Footnotes
F1: Transaction pursuant to an existing 10b5-1 trading plan dated May 26, 2023.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.19 to $88.01, inclusive. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: This number includes unvested restricted stock units previously reported.